SZSE Ticker: 002294

Shenzhen Salubris Pharmaceuticals Co., Ltd.

深圳信立泰药业股份有限公司

信立泰

SALUBRIS

Listing Date: 2009-09-10

Board: SME

Industry Classification: Manufacturing

Financiers are optimistic about buying 4 shares, accounting for over 30% of the transaction_ Oriental Fortune Net

Financiers are optimistic about buying 4 shares, accounting for over 30% of the transaction_ Oriental Fortune Net

China Health Bridge has many questions about the impact of the IPO: Who is the biggest beneficiary of the surprise dividend? How to crack the excessive dependence on a single product for revenue? How to make up for the shortcomings of compliance? IPO Watch-News Channel-Hexun.com

Xinlitai Bio, a cardiovascular and cerebrovascular innovative device platform, completed a strategic investment of hundreds of millions of yuan in the A round of investment in China.com

Xinlitai Bio, a cardiovascular and cerebrovascular innovative device platform, completed a strategic investment of hundreds of millions of yuan in the A round of Shenzhen_Sina Technology_Sina Network

Shanghai and Shenzhen stock market trading tips (April 27)

Has the Nuggets innovative drug Xinlitai new drug SAL0114 for the treatment of depression been out of the pain of centralized procurement after the clinical performance has rebounded sharply? every net

Has Xinlitai's new drug SAL0114 for the treatment of depression got out of the pain of centralized procurement after its clinical performance has rebounded sharply?

Xinlitai's new drug for depression, SAL0114 tablets, has been out of the pain of centralized procurement after the clinical performance has rebounded sharply

Has Xinlitai's new drug SAL0114 for the treatment of depression got out of the pain of centralized procurement after its clinical performance has rebounded sharply? _Finance Bay EHZ / Financial Diamond Value Drive

Has the Nuggets innovative drug Xinlitai new drug SAL0114 for the treatment of depression been out of the pain of centralized procurement after the clinical performance has rebounded sharply? every net

Has the Nuggets innovative drug Xinlitai new drug SAL0114 for the treatment of depression been out of the pain of centralized procurement after the clinical performance has rebounded sharply?

Has Xinlitai's new drug SAL0114 for the treatment of depression got out of the throes of centralized procurement after its clinical performance rebounded sharply? , Yushu altitude, Yushu Tibetan Autonomous Prefecture, jade bracelet prices, jade bracelets

A-share Toutiao listed company (4.22) Stock Financial Industry

Xinlitai (002294.SZ) obtained the drug registration certificate for teriparatide injection_Individual Stock Information_Market_Zhongjin Online

Xinlitai (002294.SZ): Subsidiary's Teriparatide Injection (Xinfutai Pro?) was approved for listing_Stock News_Market Gold Online

The main capital of 4.355 billion yuan is withdrawn from the pharmaceutical and biological sector today – yqqlm

The biomedical sector fell 1.63%, Nanjing Hi-Tech rose 6.14% to top the list – yqqlm

A-share Toutiao listed company (4.20)-

33 quarterly reports are good, 7 shares deduct non-net profit more than doubled-CFi.CN Zhongcai Network

33 quarterly reports are good, 7 shares deduct non-net profit more than doubled-CFi.CN Zhongcai Network

Want to see more data? Registered subscribers can see all the data.